Trial Profile

A phase III, single-blind, randomized comparative clinical trial of efficacy and safety of remimazolam versus propofol

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remimazolam (Primary) ; Propofol
Indications General anaesthesia
Focus Registrational; Therapeutic Use
Sponsors Hana Pharm

Most Recent Events

12 Aug 2020 According to a PAION media release, licensee Hana Pharm submitted a market approval dossier in general anesthesia in December 2019. Market approval is currently expected in 2020.
08 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to a PAION media release.
22 Mar 2018 Status changed from planning to recruiting,According to PAION media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com